Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
46,752,465
-
Total 13F shares
-
7,927,898
-
Share change
-
-457,611
-
Total reported value
-
$42,334,510
-
Put/Call ratio
-
4.4%
-
Price per share
-
$5.34
-
Number of holders
-
68
-
Value change
-
-$3,223,880
-
Number of buys
-
34
-
Number of sells
-
17
Institutional Holders of Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) as of Q3 2024
As of 30 Sep 2024,
Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) was held by
68 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,927,898 shares.
The largest 10 holders included
TANG CAPITAL MANAGEMENT LLC, GREAT POINT PARTNERS LLC, BlackRock, Inc., VANGUARD GROUP INC, Altium Capital Management LP, SPHERA FUNDS MANAGEMENT LTD., GEODE CAPITAL MANAGEMENT, LLC, Caligan Partners LP, Schonfeld Strategic Advisors LLC, and STATE STREET CORP.
This page lists
65
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.